Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$6.63M
• Dividend Yield: N/A
• Average Volume (3M): 78.67K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 165,771,560
• 10 Day Avg. Volume: 85,143
• 30 Day Avg. Volume: 78,671
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: C$0.00 ▼(-100.00% Downside)

Kane Biotech's overall stock score is primarily impacted by its severe financial difficulties, with negative equity and cash flow challenges posing significant risks. Technical analysis indicates a bearish trend, while valuation metrics further reflect the company's struggles. While there are some positive corporate events, they are insufficient to offset the overarching financial and operational issues.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech Inc. (KNE) is a biotechnology company based in Canada that specializes in the development of innovative antimicrobial products aimed at addressing biofilm-related challenges in healthcare and consumer markets. The company focuses on creating solutions that prevent and treat infections, particularly those caused by antibiotic-resistant bacteria. Kane Biotech's core products include its proprietary antimicrobial technologies, which are applicable in various sectors such as medical devices, dental care, and veterinary products.

How the Company Makes Money

Kane Biotech generates revenue primarily through the sale of its antimicrobial products and technologies to healthcare providers, dental practitioners, and the veterinary market. The company has established key partnerships with organizations in the healthcare sector to enhance the distribution of its products. Additionally, Kane Biotech may engage in licensing agreements for its proprietary technologies, which provide a significant revenue stream. The company also explores research grants and funding opportunities to support its product development initiatives, contributing to its overall earnings.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech is facing severe financial challenges with significant net losses, high leverage, negative equity, and ongoing cash burn. The income statement reveals growing revenues but worsening profitability. The balance sheet indicates high leverage and negative equity, and cash flow statements highlight operational inefficiencies.

Income Statement

The income statement reveals significant challenges with profitability. Despite a notable revenue increase in TTM, from 2024 to 2025, with a growth rate of approximately 17.32%, net losses have expanded considerably, with a negative net profit margin of 310.71%. The gross profit margin is at 33.21%, indicating some ability to cover direct costs, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet of Kane Biotech indicates financial instability. The company is highly leveraged, with negative stockholders' equity of -$1,134,019 in TTM, leading to an undefined debt-to-equity ratio. The negative equity ratio suggests liabilities exceed assets, posing a considerable risk. The historical trend shows worsening equity positions.

Cash Flow

The cash flow statement presents challenges, primarily due to negative operating cash flow, which is substantially higher than net income, indicating inefficiencies in core operations. Free cash flow remains negative, although there is a slight improvement in free cash flow growth rate. Nonetheless, free cash flow to net income is negative, reflecting ongoing cash burn.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.08M	148.98K	2.67M	1.61M	1.34M
Gross Profit	653.63K	109.47K	1.41M	568.44K	526.86K
EBITDA	-3.71M	-3.23M	-2.95M	-4.25M	-3.65M
Net Income	-3.02M	-5.03M	-3.89M	-4.60M	-3.72M
Balance Sheet
Total Assets	2.49M	5.68M	5.62M	6.13M	5.04M
Cash, Cash Equivalents and Short-Term Investments	358.81K	749.25K	1.10M	1.15M	1.01M
Total Debt	2.18M	9.26M	6.86M	4.71M	2.25M
Total Liabilities	4.12M	14.09M	9.76M	7.70M	3.96M
Stockholders Equity	-1.63M	-10.56M	-6.52M	-3.89M	-1.49M
Cash Flow
Free Cash Flow	-4.14M	-3.23M	-3.13M	-2.64M	-4.07M
Operating Cash Flow	-4.11M	-3.22M	-3.04M	-2.29M	-3.94M
Investing Cash Flow	10.27M	-116.14K	-107.55K	-373.55K	-166.11K
Financing Cash Flow	-7.69M	2.98M	3.10M	2.81M	4.28M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.05, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.08 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.41B	-0.29	-44.86%	2.30%	23.46%	-0.02%
BLAB	42 Neutral	C$13.79M	―	-175.45%	―	-3.93%	-575.24%
HEM	41 Neutral	C$14.17M	―	34.47%	―	―	-63.05%
KNE	41 Neutral	C$6.63M	―	-813.02%	―	―	―
BETR	21 Underperform	C$12.91M	―	26.73%	―	―	62.66%

Kane Biotech Corporate Events

Kane Biotech Highlights Promising revyve® Findings at Wound Care Conferences

Kane Biotech recently showcased promising preclinical and clinical findings of their product revyve® at two major North American wound care conferences. The data presented highlighted significant reductions in wound size, pain, and protease activity, showcasing revyve®’s potential in transforming wound care. The company emphasized the clinical and commercial potential of revyve®, reinforcing their market support plan and innovation in the wound care industry.

Kane Biotech to Showcase Innovations at Advanced Wound Care Summit

Kane Biotech announced that its Interim CEO, Dr. Robert Huizinga, will present at the Advanced Wound Care Summit USA, highlighting their innovative wound care solutions. This participation underscores Kane Biotech’s commitment to advancing wound care technology and potentially enhancing its industry positioning by showcasing its breakthrough science to key stakeholders.

Kane Biotech Converts Loan to Debenture and Announces AGM Results

Kane Biotech has converted a $1 million unsecured demand loan from an insider into a 3% unsecured convertible debenture due in 2030, pending final approval from the TSX Venture Exchange. Additionally, at their recent Annual and Special Meeting of Shareholders, all resolutions were passed with 98% or higher approval, including the election of three new and three existing board directors, signaling strong shareholder support and potential strategic growth.

Kane Biotech Reorganizes Distribution and Financial Strategies Amid Clinical Advancements

Kane Biotech has terminated its distribution agreement with ProgenaCare due to breaches and is working to reestablish its U.S. distribution network. The company is also addressing a default notice from PrairiesCan regarding a repayable contribution agreement and is restructuring its repayment schedule. Additionally, Kane Biotech is converting a $1 million loan into a convertible debenture, subject to regulatory approval, and is progressing with clinical plans for its revyve™ Antimicrobial Wound Gel products in the U.S. market.

Kane Biotech Reports Q1 2025 Results Amid Restructuring Efforts

Kane Biotech reported a significant increase in revenue for the first quarter of 2025, primarily from contract animal health manufacturing, despite a net loss. The company is undergoing a restructuring strategy to focus on its revyve™ product line and has implemented cost-reduction initiatives to strengthen its financial position. The departure of the CEO and subsequent legal action are notable developments, but the company remains committed to advancing its pipeline and creating long-term value for stakeholders.